Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06097455 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma

Study acronym: CARTD-BG-1
StatusNot Yet Recruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 26, 2023 (before its estimated April 15, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Re-verified, no change to tracked fieldsv2
  2. Study First Submitted
ths study consist in testing a CAR T therapy (ARI0003 cells (antiCD19 and antiBCMA) in patients suffering relapsed NHL (that means that symptoms of NHL reappeared ) or refractory (that means that they did not respond to other treatments). This is a first in human study.
Trial Details
NCT Number NCT06097455
Lead Sponsor Fundacion Clinic per a la Recerca Biomédica
Conditions
(from sponsor)		 Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
Related terms Lymphoma, Non-Hodgkin
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov